Literature DB >> 16678889

In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway.

Giorgi Kedia1, Stefan Uckert, Friedemann Scheller, Teimuraz Chigogidze, Lauri Managadze, Udo Jonas, Michael C Truss.   

Abstract

OBJECTIVES: To examine the effects of some nitric oxide-donating agents, as well as the C-type natriuretic peptide (CNP), on isolated human prostatic tissue. To date, guanylyl cyclases and cyclic guanosine monophosphate (cGMP)-degrading phosphodiesterases represent important target proteins for the development of new drugs for the treatment of lower urinary tract symptoms and benign prostatic hyperplasia.
METHODS: Using the organ bath technique, the effects of sodium nitroprusside, S-nitrosoglutathione, S-nitrosocysteine, linsidomine, and CNP (1 nM to 1.0/10 microM) on the tension induced by norepinephrine of prostatic tissue strips were investigated. The tissue was also exposed to three different concentrations of the drugs, and the production of cGMP and cyclic adenosine monophosphate (cAMP) was determined.
RESULTS: The tension induced by 40 microM norepinephrine of the isolated prostatic tissue was dose dependently reversed by the drugs. The rank order of potency was sodium nitroprusside more than S-nitrosoglutathione more than linsidomine more than S-nitrosocysteine, which was equal to CNP (1 microM). The reversal of tension induced by the greatest drug concentrations ranged from 50% relaxation with sodium nitroprusside to 42% relaxation with CNP. The relaxing effects of the drugs were paralleled by a 2-fold to 40-fold and 2-fold to 45-fold increase in tissue levels of cAMP and cGMP, respectively.
CONCLUSIONS: Our results provide further evidence that cGMP and cAMP are involved in the control of the normal function of human prostatic smooth muscle. Our findings may provide new strategies for future therapeutics used in the treatment of lower urinary tract symptoms and bladder outlet obstruction secondary to benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678889     DOI: 10.1016/j.urology.2005.12.002

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  [Significance of phosphodiesterase isoenzymes in the control of human detrusor smooth muscle function. An immunohistochemical and functional study].

Authors:  S Uckert; K Sigl; E S Waldkirch; P Sandner; E Ulbrich; M Oelke; C G Stief; M A Kuczyk
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

2.  Dendroaspis natriuretic peptide relaxes gastric antral circular smooth muscle of guinea-pig through the cGMP/cGMP-dependent protein kinase pathway.

Authors:  Chun-Yu Cai; Zheng-Xu Cai; Xin-Yi Gu; Lu-Juan Shan; Yong-Xiao Wang; Xue-Zhe Yin; Qing-Hui Qi; Hui-Shu Guo
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 3.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 4.  The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms.

Authors:  George T Kedia; Stefan Uckert; Udo Jonas; Markus A Kuczyk; Martin Burchardt
Journal:  World J Urol       Date:  2008-07-08       Impact factor: 4.226

Review 5.  Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction.

Authors:  Serap Gur; Philip J Kadowitz; Wayne J G Hellstrom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

Review 7.  S-Nitroso-N-acetyl-L-cysteine ethyl ester (SNACET) and N-acetyl-L-cysteine ethyl ester (NACET)-Cysteine-based drug candidates with unique pharmacological profiles for oral use as NO, H2S and GSH suppliers and as antioxidants: Results and overview.

Authors:  Dimitrios Tsikas; Kathrin S Schwedhelm; Andrzej Surdacki; Daniela Giustarini; Ranieri Rossi; Lea Kukoc-Modun; George Kedia; Stefan Ückert
Journal:  J Pharm Anal       Date:  2017-12-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.